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Introduction {#s1}
============

Arsenic exposure in humans is recognized as a major public health issue \[Agency for Toxic Substances and Disease Registry ([@c5]; World Health Organization ([@c73]), where tens of millions of people worldwide are exposed at concentrations above maximum contaminant levels ([@c51]). Chronic exposure through drinking water increases the mortality rate ([@c3]) owing to the increased incidence of several cancers ([@c1]) ([@c61]; [@c69]), cardiovascular disease ([@c46]), impairment of lung ([@c29]) ([@c4]) and liver ([@c42]) function, defective immune responses ([@c2]; [@c15]), and diabetes ([@c48]). Of particular concern is the link between arsenic exposure and atherosclerosis. In fact, people exposed to even low concentrations of arsenic are at risk of developing atherosclerosis ([@c46]).

Arsenic is biotransformed through a series of oxidation and methylation reactions primarily catalyzed by arsenic (3) methyltransferase (As3MT) ([@c68]). *As3MT* is conserved from bacteria to mammals ([@c68]). Thus, humans are exposed to methylated intermediates generated by bacteria found in the environment ([@c52]). The methylation reaction uses *S*-adenosyl-[l]{.smallcaps}-methionine (SAM) as the methyl donor and produces intermediate compounds that include both monomethylated (MMA V and MMA III) and dimethylated (DMA V and DMA III) forms of arsenate and arsenite. Several different molecular mechanisms have been proposed for the reaction, some involving glutathionylated-arsenic intermediates ([@c11]; [@c16]; [@c25]). Regardless of the exact reaction, there is a consensus regarding the importance of the As3MT enzyme in arsenic methylation. *As3mt* knockout mice have altered retention and distribution of arsenic, with significantly decreased production of methylated intermediates ([@c18]). Historically, this reaction was considered a detoxification process; however, it is now recognized that some intermediate species are more toxic than inorganic arsenic ([@c66]). Nevertheless, the relative contribution of each intermediate arsenical to specific outcomes has not been defined.

The capacity to methylate arsenic has been epidemiologically linked to cardiovascular diseases. Lower methylation capacity, indicated by higher urinary MMA% or lower urinary DMA%, was associated with increased risk of fatal and nonfatal cardiovascular disease, including atherosclerosis ([@c13]). The same group reported a linear dose--response relationship between urinary MMA% and carotid intima media thickness (cIMT), a surrogate measure of atherosclerosis, and they proposed that incomplete methylation influences atherosclerosis ([@c12]). Importantly, human *AS3MT* polymorphisms were linked to differential arsenic methylation efficacy ([@c20]). An interaction between several *AS3MT* single nucleotide polymorphisms (SNPs), arsenic content in well-drinking water, and cIMT has been reported ([@c74]), although it was not statistically significant after adjusting for multiple comparisons. These data are suggestive that certain populations may be at greater risk for cardiovascular consequences of arsenic exposure.

We utilized the $\text{apoE}^{- / -}$ mouse model to address the role of arsenic biomethylation in arsenic-induced atherosclerosis. Previously, we observed increased atherosclerotic plaque formation in the $\text{apoE}^{- / -}$ mouse model after exposure to $200\,\text{ppb}$ (parts per billion; micrograms/liter) inorganic sodium arsenite, an environmentally relevant concentration ([@c32]). Here, we provide data that methylated arsenicals are also proatherogenic. Importantly, we show that As3MT expression is required for arsenic-induced atherosclerosis.

Methods {#s2}
=======

Mice {#s2.1}
----

$B6.129P2 - apoE^{tm1Unc}/J$ ($\text{apoE}^{- / -}$) male mice were obtained from Jackson laboratory. ${\mathit{As}3\textit{mt}}^{- / -}$ mice (C57BL/6 background) were kindly provided by D. Thomas (U.S. Environmental Protection Agency, Research Triangle Park, NC, USA). $\mathit{apoE}^{- / -}{\mathit{As}3\mathit{mt}}^{- / -}$ double knockout (DKO) mice were created in our facility. All experiments were performed with male mice randomly selected from different litters. Purchased mice were acclimatized to housing conditions under a 12-h light/12-h dark cycle for at least 2 wk before experiments. All mice were fed *ad libitum*. The experimental protocol was approved by the McGill Animal Care Committee, and animals were handled in accordance with institutional guidelines. The McGill Animal Care Committee is certified by the Canadian Council on Animal Care. All animals were treated humanely and with regard for alleviation of suffering.

Exposure Protocol {#s2.2}
-----------------

Four-week-old $\text{apoE}^{- / -}$ or DKO mice were maintained for 13 wk on tap water or on tap water containing $200\,\text{ppb}$ *m*-sodium arsenite ($0.35\;{mg}/L$ $\text{NaAsO}_{2}$; Sigma-Aldrich), disodium methyl arsonate hexahydrate DSMA (MMA V; $0.78\;{mg}/L$; Chem Service), monomethyl arsenous acid (MMA III; $0.37\;{mg}/L$) synthesized as described ([@c24]) or cacodylic acid (DMA V; $0.43\;{mg}/L$; Sigma-Aldrich). Solutions containing arsenic were refreshed every 2 -- 3 days to minimize oxidation. The mice were fed with AIN-76A purified diet containing 5% fat (by weight) with no cholesterol for all of the experiments (Harlan Laboratories Inc.), with the exception of one group of DKO mice fed with a high-fat diet (20% cocoa butter, 0.5% cholesterol, Harlan Laboratories Inc.).

Bone Marrow Transplantations {#s2.3}
----------------------------

Recipient $\text{apoE}^{- / -}$ or DKO male mice were lethally irradiated (10 Gy) at 5 wk of age and were injected with donor bone marrow cells 24 h after irradiation. Donors were euthanized, and tibias and femurs were flushed with phosphate-buffered saline (PBS). The suspension was passed $\geq 5$ times through an $18–\text{gauge}$ needle, then through a cell strainer ($70\;\mu m$) placed into a $50–{mL}$ tube, and centrifuged at $210 \times \mathit{g}$ for 3 min. The cell pellet was resuspended at a density of $2.5 \times 10^{7}\,\text{cells}/\text{ml}$, and $200\;\mu l$ per mouse was injected via the tail vein. After a 4-wk recovery period, the animals were exposed to tap water or to tap water containing $200\,\text{ppb}$ $\text{NaAsO}_{2}$. One group of $\text{apoE}^{- / -}$ mice reconstituted with DKO bone marrow was fed a high-fat diet.

Plasma Analyses {#s2.4}
---------------

Blood ($0.6\;{mL}$) was obtained by cardiac puncture, and plasma was isolated using collection tubes (EDTA BD Vacutainer SST; Becton Dickinson). Cholesterol, high- and low-density lipoproteins (HDL and LDL, respectively), triglycerides, and liver enzymes \[aspartate aminotransferase (AST) and alanine aminotransferase (ALT)\] were assessed by the Animal Resources Centre (McGill University, Montréal, Quebec, Canada).

Atherosclerotic Lesion Characterization {#s2.5}
---------------------------------------

Characterization of the atherosclerotic lesions was performed as previously described ([@c32]). Briefly, the fixed aorta was rinsed with ultrapure water, then cut longitudinally and stained *en face* with Oil Red O (Electronic Microscopy Sciences). Images were acquired using INFINITY CAPTURE software and camera (Lumenera). Percentage of lesion area of the aortic arch, defined as the region from the first intercostal arteries to the ascending arch, was evaluated using ImageJ software \[National Institutes of Health (NIH)\]. The atherosclerotic lesions were also evaluated within the aortic sinus from $\geq 5$ animals. Rinsed, fixed, and embedded frozen hearts were processed as previously described ([@c32]). Consecutive $6 - \mu m$ cryosections were sliced from the aortic base throughout the aortic sinus, where 3--5 valve sections per animal were stained with Oil Red O to visualize the plaque areas and were analyzed for their lipid content. Aortic valves were also stained and analyzed for their collagen content (type I and type III) using picrosirius red (Polysciences) ([@c32]).

*In Situ* Immunofluorescence {#s2.6}
----------------------------

Smooth muscle cell (SMC) and macrophage contents were assessed within the entire plaque area as previously described ([@c32]). Briefly, aortic sinus sections were rinsed and blocked with 3% bovine albumin serum (Sigma-Aldrich), incubated with primary antibody \[1:200 for monoclonal $\text{anti} - \alpha - \text{smooth}$ muscle cell actin \[clone 1A4\], 1:50 for MOMA-2 (Abcam)\], rinsed, and incubated with fluorescently labeled secondary antibodies (1:500; Invitrogen). The presence of the immunofluorescent marker from at least 3 sections per animal was quantified using ImageJ software (NIH) and was expressed as a percentage of the total lesion area.

*In Situ* Dihydroethidium Staining {#s2.7}
----------------------------------

Frozen aortic sinus sections were stained with $2\;\mu M$ dihydroethidium (DHE) (ThermoFisher Scientific) in PBS and were analyzed immediately using a fluorescence microscope. The presence of the fluorescent marker from $\geq 5$ sections per animal was quantified using ImageJ software (NIH): images were batch-processed by converting to 32-bit images, the colors were inverted to adjust the thresholds on a white background, and vessel perimeters were demarcated. Intensity was assessed and expressed as percentage of the total vessel area.

Primary Bone Marrow-Derived Macrophages (BMDMs) Differentiation and Polarization {#s2.8}
--------------------------------------------------------------------------------

Bone marrow from $\text{apoE}^{- / -}$ or DKO mice was isolated from the femur and tibia of 10- to 12-wk-old old mice. Bones were flushed with RPMI 1,640, and a single-cell suspension was created by passing it 5 times through an 18G needle. The cell suspension was filtered and centrifuged at $1,000\;\text{rpm}$ for 3 min. Pelleted cells were suspended in Roswell Park Memorial Institute (RPMI) 1640 medium (Wisent, Inc) plus 10 % fetal bovne serum (FBS) (Wisent, Inc) plus penicillin/streptomycin (Wisent, Inc) and were plated to perform a monocyte-enriching adherence step for 1 h. Next, nonadherent cells were removed, fresh medium was added with $50\;\text{ng}/{mL}$ of macrophage colony stimulating factor (M-CSF) (Peprotech®), and the cells were cultured for 5 d. Medium was refreshed every 2--3 d. After 5 d, cells were kept in M-CSF for M0 or were polarized toward M1 using interferon gamma ($\text{IFN} - \gamma$) or toward M2 using interleukin 4 (IL-4) ($50\;\text{ng}/{mL}$ $\text{IFN} - \gamma$, Peprotech®, and $10\;\text{ng}/{mL}$ IL-4, Peprotech®, respectively) for an additional 48 h.

Staining for Cellular Lipid Accumulation {#s2.9}
----------------------------------------

Unpolarized (M0) BMDMs from $\text{apoE}^{- / -}$ or DKO mice was isolated as described above and cultured on cover slips for 5 d in M-CSF with or without $\text{NaAsO}_{2}$. Then, cells were exposed to $2.5\mu M$ 7-ketocholesterol for a further 24 h. Next, cells were stained with Oil Red O for 40 min, counterstained with hematoxylin for 2 min, and rinsed with PBS before mounting the slides. Images were acquired using INFINITY CAPTURE software and camera (Lumenera). At least 200 macrophages in 2 different fields were counted, and the results were expressed as a percentage of Oil Red O--positive cells per total cell number.

Endothelial Cell Isolation and Culture {#s2.10}
--------------------------------------

This protocol was adapted from a protocol described by Robins et al. ([@c58]). Endothelial cells were isolated from lungs of 8 -- 10-wk-old $\text{apoE}^{- / -}$ or DKO mice. The lungs were cut into small pieces and incubated at 37°C for 60 min in 0.1% collagenase A (Roche Diagnostics) in RPMI medium plus penicillin/streptomycin. The suspension was transferred into a $50–{mL}$ tube, passed 15 times through an $18 - \text{gauge}$ needle, and then through a cell strainer ($70\;\mu m$), and was then centrifuged at $210 \times \mathit{g}$ for 5 min. The supernatant was removed, and the cells were plated in $75{- {cm}}^{2}$ tissue culture flasks coated with 0.1% gelatin (Millipore) and grown for 1 wk in 50% Dulbecco\'s Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F12; Wisent, Inc) supplemented with 10% FBS and penicillin/streptomycin and 50% Endothelial Growth Medium SingleQuot (EGM-2 SingleQuot) medium (Lonza). Endothelial cells were selected by performing two consecutive immunoisolation steps using magnetic beads conjugated with anti--intercellular adhesion molecule 2 (anti-ICAM-2) antibody (BD Biosciences PharMingen) and were plated into $75{- {cm}}^{2}$ tissue culture--gelatin-coated flasks. Endothelial cells were used for experiments at passage 4. Cultures were serum-starved for 24 h before experiments.

Smooth Muscle Cell Isolation and Culture {#s2.11}
----------------------------------------

SMCs were isolated from the thoracic aorta of 8- to 10-wk-old $\text{apoE}^{- / -}$ and DKO male mice ([@c57]). After removal of the adventitia, the tunica media was digested with $3\;{mg}$ collagenase (Worthington Biochemical Corporation) and $3\;{mg}$ elastase (Sigma-Aldrich) for 0.5 h at 37°C. The suspension was passed $\geq 10$ times through an $18 - \text{gauge}$ needle, then through a cell strainer ($70\;\mu m$) into a $50–{mL}$ tube and centrifuged at $836 \times \mathit{g}$ for 2 min. The supernatant was removed, and the cells were plated into $25{- {cm}}^{2}$ tissue culture flasks in DMEM (Wisent, Inc) supplemented with 10% FBS and penicillin/streptomycin for 2 wk. Experiments were performed at passage 3 or passage 4. Cultures were serum-starved for 24 h before experiments.

*In Vitro* DHE Staining {#s2.12}
-----------------------

Primary cells were isolated and cultured as described above. Cells were stained as described elsewhere ([@c64]). Briefly, BMDMs, SMCs, or endothelial cells were stained with $5\;\mu M$ DHE in media for 10 min, after which $200\,\text{ppb}$ $\text{NaAsO}_{2}$, MMA III, DMA V, or DMA III was added for a further 30 min. DMA III was synthesized as described ([@c22]) and utilized immediately. Rotenone (Sigma Aldrich) at $10\mu M$ and menadione (Sigma Aldrich) at $200\mu M$ were used as positive controls. Antioxidants ($1\text{mM}$ Tempol or $5\,\text{mM}$ *N*-acetylcysteine) were added for 10 min before exposure. Images were obtained immediately using a fluorescence microscope. The relative fluorescence was used to determine changes in DHE oxidation normalized to the number of cells in the field.

Gene Expression {#s2.13}
---------------

Total RNA was isolated from BMDMs using an RNeasy kit (Qiagen). Complementary DNA (cDNA) was prepared from total RNA using the iScript cDNA synthesis kit (Bio-Rad). Gene expression was analyzed by real-time polymerase chain reaction (qPCR) using the Applied Biosystems 7500 Fast RT-PCR system and Fast SYBR Green Master Mix (Life Technologies). Experiments were performed using qPCR primers designed and purchased from Integrated DNA Technologies: m36B4 (5′TCATCCAGCAGGTGTTTGACA3′ and 5′GGCACCGAGGCAACAGTT3′, efficiency 98.55%, slope $- 3.3$), As3mt (5′GAAAACTGCCGAATTTTGGA3′ and 5′GCCGTGGAGAAAAGTCACAT3′, efficiency 97.99%, slope $- 3.3$). Primers were validated using standard curves over 5 logs of murine C57BL6 liver cDNA. Only primers with single peaks (and no primer dimers) in melt curves were used. Experiments were performed using three technical replicates. Data were normalized to the housekeeping gene m36B4. Fold change in gene expression was determined by the $2^{- \Delta\Delta\text{Ct}}$ method using naïve gene expression as the reference sample.

Protein Quantification and Immunoblotting {#s2.14}
-----------------------------------------

Cells were lysed using radioimmunoprecipitation assay (RIPA) buffer ($50\,\text{mM}$ Tris-HCl, pH 8.0, with $150\,\text{mM}$ sodium chloride, 1.0% Igepal CA-630 (NP-40), 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate) at 4°C. After sonication (Sonic Dismembrator; Fischer Scientific) with 3 pulses at 10% for 10 s, the cell lysates were centrifuged at $15,871 \times \mathit{g}$ for 10 min. The supernatants were collected, and protein concentrations were quantified with the Bio-Rad protein assay (Bio-Rad). Samples were boiled at 95°C, and equal amounts of protein ($50\;\mu g$) were loaded on a 10% sodium dodecyl sulfate--polyacrylamide gel electrophoresis (SDS-PAGE) gel. Proteins were transferred to a nitrocellulose membrane (Bio-Rad, Mississauga, CA). Membranes were blocked for 30 min with 5% milk/Tris-buffered saline (TBS) plus 10% TWEEN 20 and probed with the primary antibody overnight at 4°C. Next, the blots were incubated with anti-rabbit antibodies (BD PharMingen) for 1 h at 20--23°C, and the signals of the target proteins were developed with chemiluminescence substrate (Amersham, GE Healthcare). GAPDH or Lamin A was used as an endogenous control to confirm equal protein loading.

Antibodies {#s2.15}
----------

As3MT polyclonal antibody was raised in rabbit using the following synthetic peptide (EpiCypher): \[C\]HGRIEKLAEAGIQSESYDIV. The amino acid in brackets was added to improve the solubility of the peptide and for coupling. Further, the peptide was conjugated to keyhole limpet hemocyanin (Sigma-Aldrich) and was sent to Pocono Rabbit Farm & Laboratory Inc. for antibody production. Rabbit serum was affinity-purified using an antigen column with a SulfoLink immobilization kit (Thermo Scientific). Commercial antibodies were used: rabbit anti-GAPDH (Life Science) and rabbit anti-Lamin A (Santa Cruz).

Arsenic Speciation in BMDMs {#s2.16}
---------------------------

Media from BMDMs were collected after 48 h of exposure to $50\text{ppb}$ $\text{NaAsO}_{2}$. Media were diluted in 0.1 volume of $150\,\text{mM}$ aqueous mercury chloride to displace trivalent As from protein thiols. After holding these samples on ice for one minute, they were deproteinized by mixing with one volume of $0.66\; M$ ice-cold perchloric acid ($\text{HClO}_{4}$)and were centrifuged for 10 min at $1,503 \times \mathit{g}$. The supernatant was sent to Columbia University (New York) for analysis. Briefly, the supernatant was mixed with mobile-phase buffer and injected onto a high performance liquid chromatography (HPLC) column connected to an inductively coupled plasma--mass spectrometry--dynamic reaction cell (ICP-MS-DRC; Perkin-Elmer). Calibration standards of As metabolite mixtures were treated the same way to achieve the same pH and composition as the deproteinized samples.

ICP-MS-DRC was coupled to HPLC and was used as a detector for six arsenic metabolites chromatographically separated by anion exchange using a Hamilton PRP-X100 column (Hamilton Company) with $10\text{mM}$ ammonium nitrate/ammonium phosphate, pH 9.1, as the mobile phase. Excellent separation power by HPLC, coupled with very low detection limits of ICP-MS-DRC, allowed us to detect AsC, AsB, MMA, DMA, ${As}^{3 +}$, and ${As}^{5 +}$, without online digestion of organic forms, with great precision down to total As concentrations of $0.1\;\mu g/L$.

Statistical Considerations {#s2.17}
--------------------------

For statistical analysis, one-way analysis of variance (ANOVA) was performed and the *p*-value was evaluated with Dunnett's test or a Bonferroni post hoc test using GraphPad Instat software. A $p - \text{value} < 0.05$ indicated statistical significance. The data are presented as the $\text{mean}\,\text{values} \pm \text{the}\,\text{standard}\,\text{error}\,\text{of}\,\text{the}\,\text{mean}\,\left( \text{SEM} \right)$

Results {#s3}
=======

Effects of Methylated Arsenicals, Inorganic Arsenic, and Arsenobetaine on Atherosclerosis and Plaque Components in the $\mathbf{a}\mathbf{p}\mathbf{o}\mathbf{E}^{- / -}$ Mouse Model {#s3.1}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Moderate ($200\,\text{ppb}$) concentrations of sodium arsenite are proatherogenic in $\text{apoE}^{- / -}$ mice, such that they increase plaque formation and alter the plaque components after 13 wk of exposure through drinking water ([@c32]). However, the potential effects of organic arsenicals in our system were unknown. Thus, we compared the methylated arsenicals MMA V, MMA III and DMA V with inorganic arsenic ($\text{NaAsO}_{2}$) by exposing $\text{apoE}^{- / -}$ mice to $200\,\text{ppb}$ of individual arsenicals in drinking water for 13 wk. The plaque formation was accessed *en face* in the aortic arch after staining with Oil Red O. Surprisingly, when compared with the control group, exposure to all of the methylated arsenicals enhanced the size of the atherosclerotic lesions ([Figure 1A](#f1){ref-type="fig"}). We further analyzed the plaque size and components in cross-sections of the aortic sinus. Here, although we observed increased plaque size in all groups, only $\text{NaAsO}_{2}$ was statistically significant ([Figure 1B](#f1){ref-type="fig"}; $p = 0.07$ for MMA V vs. control). We previously observed that $\text{NaAsO}_{2}$ exposure increased lipid content within the plaques without a concomitant increase in macrophage number, suggesting that each macrophage accumulated more lipids per cell ([@c32]). Similar analyses for lipid content by Oil Red O staining within plaques showed that methylated arsenicals increased lipids to the same extent as $\text{NaAsO}_{2}$ ([Figure 1C](#f1){ref-type="fig"}) despite no change in macrophages per plaque area as assessed by immunofluorescent staining ([Figure 1D](#f1){ref-type="fig"}). We also evaluated collagen and SMCs, increases in which promote plaque stability ([@c23]; [@c38]). Collagen content was reduced in groups exposed to $\text{NaAsO}_{2}$ and monomethylated arsenicals (MMA V and MMA III), but not in the DMA V--exposed groups ([Figure 1E](#f1){ref-type="fig"}). Interestingly, SMC content was decreased in all arsenic-exposed groups, reaching statistical significance only in $\text{NaAsO}_{2} - \text{exposed}\,\text{mice}$ ([Figure 1F](#f1){ref-type="fig"}).

![Effects of methylated arsenicals, inorganic arsenic, and arsenobetaine on atherosclerosis and plaque components in the $\text{apoE}^{- / -}$ mouse model. Four-week-old $\text{apoE}^{- / -}$ mice were exposed to $200\,\text{ppb}$ arsenicals \[*m*-sodium arsenite ($\text{NaAsO}_{2}$), monomethyl arsenic (MMA) V, MMA III, dimethyl arsenic (DMA V) or arsenobetaine (arsenob)\] or maintained on tap water for 13 wk. Percent lesion area of the aortic arch (*A*) or aortic sinus (*B*) was evaluated via staining with Oil Red O. Lipid content (*C*), macrophage (*D*), collagen (*E*), and smooth muscle cell (*F*) content was evaluated in the aortic sinus relative to the total lesion area. The scale bar represents $100\;\mu m$. Values are expressed as the $\text{mean} \pm \text{standard}\,\text{error}\,\text{of}\,\text{the}\,\text{mean}\,\left( \text{SEM} \right)$. \*$p < 0.05$; \*\*$p < 0.01$; \*\*\*$p < 0.001$; \*\*\*\*$p < 0.0001$ relative to their own control.](EHP806_f1){#f1}

Arsenobetaine is also an organic arsenical and is the main arsenic-containing compound found in many fish ([@c45]) ([@c49]). However, it is not biotransformed by As3MT in laboratory animals ([@c71]). We tested whether arsenobetaine also acted as a proatherogen. Interestingly, arsenobetaine exposure did not increase plaque formation in the arch or sinus ([Figure 1A and 1B](#f1){ref-type="fig"}). Together, these observations indicate that methylated arsenicals are proatherogenic and can cause changes in plaque components in a manner similar to that of $\text{NaAsO}_{2}$. Further, the lack of proatherogenic activity by arsenobetaine suggests that biotransformation by As3MT is important.

Effects of *As3mt* Deletion on Arsenic-Induced Atherosclerosis {#s3.2}
--------------------------------------------------------------

To study the relative contribution of As3MT in arsenic-induced atherosclerosis, we developed a double knockout mouse model by crossing ${{As}3\text{mt}}^{- / -}$ mice with $\text{apoE}^{- / -}$ mice. The DKO mice were viable and were born at 1:1 a sex ratio with no difference in litter size compared with $\text{apoE}^{- / -}$ mice (see Figure S1A). We confirmed the lack of As3mt expression in liver extracts from DKO mice (with and without $\text{NaAsO}_{2}$ exposure) (see Figure S1B), as well as the lack of arsenic methylation, by measuring methylated intermediates in the urine (Fig. S1C). No differences were observed in the body weight (see Figures S1D and S1E), circulating lipid profiles, liver enzymes, or complete blood counts (see Tables S1 and S2) between the DKO mice and the $\text{apoE}^{- / -}$ mice.

We then compared $\text{apoE}^{- / -}$ and DKO mice exposed to tap water or to $200\,\text{ppb}$ $\text{NaAsO}_{2}$, MMA III, or DMA V for 13 wk and measured the extent of atherosclerotic plaque. In contrast to $\text{apoE}^{- / -}$ mice, the DKO mice exposed to $\text{NaAsO}_{2}$ exhibited no increased plaque formation in either the aortic arch ([Figure 2A](#f2){ref-type="fig"}) or the aortic sinus ([Figure 2B](#f2){ref-type="fig"}) compared with tap water--exposed mice. Moreover, exposure to methylated intermediate arsenicals did not rescue the phenotype ([Fig 2A and 2B](#f2){ref-type="fig"}). Importantly, DKO mice were specifically protected from arsenic-enhanced atherosclerosis because a high-fat diet (HFD) enhanced plaque formation in these animals ([Figure 2A and 2B](#f2){ref-type="fig"}). Of note, in the aortic sinus, control DKO mice had slightly more plaque area than control $\text{apoE}^{- / -}$ mice ($p = 0.0813$; [Figure 2B](#f2){ref-type="fig"}), although this finding was not observed in the aortic arch.

![Effects of *As3mt* deletion on arsenic-induced atherosclerosis. Four-week-old $\text{apoE}^{- / -}$ and double knockout (DKO) mice were exposed to $200\,\text{ppb}$ arsenicals \[*m*-sodium arsenite ($\text{NaAsO}_{2}$, monomethyl arsenic (MMA) III or dimethyl arsenic (DMA V)\] or maintained on tap water for 13 wk. An additional group of DKO mice was fed a high-fat diet (HFD) and kept on tap water. Percent lesion area of the aortic arch (*A*) or aortic sinus (*B*) was evaluated via staining with Oil Red O. Smooth muscle cell (*C*), collagen (*D*), lipid (*E*), and macrophage (*F*) content were evaluated in the aortic sinus relative to the total lesion area. Representative pictures are shown. The scale bar represents $100\;\mu m$. Bone marrow--derived macrophages from $\text{apoE}^{- / -}$ or DKO background were cultured for 5 days with or without 0.1 or $0.6\;\mu M$ (10 or $50\,\text{ppb}$) $\text{NaAsO}_{2}$, after which cultures were challenged with 7-ketocholesterol for 24 h. The number of cells staining positive for lipids expressed relative to total cell amount per field was quantified (*G*). Values are expressed as the $\text{mean} \pm \text{standard}\,\text{error}\,\text{of}\,\text{the}\,\text{mean}\,\left( \text{SEM} \right)$. \*$p < 0.05$; \*\*$p < 0.01$; \*\*\*$p < 0.001$; \*\*\*\*$p < 0.0001$ relative to their own control.](EHP806_f2){#f2}

Next, we evaluated whether DKO mice were also protected from arsenic-induced changes in plaque composition. In $\text{apoE}^{- / -}$ mice, both inorganic and methylated arsenicals increased lipid accumulation per macrophage, with concomitant decreases in SMCs and collagen ([Figure 1C-F](#f1){ref-type="fig"}). In contrast, the DKO mice exposed to arsenicals exhibited no decrease in the number of SMCs ([Figure 2C](#f2){ref-type="fig"}), and only $\text{NaAsO}_{2} - \text{exposed}\,\text{mice}$ exhibited reduced collagen content ([Figure 2D](#f2){ref-type="fig"}). Surprisingly, plaques from control, unexposed DKO mice had fewer SMCs and less collagen than control $\text{apoE}^{- / -}$ mice ([Figure 2C and 2D](#f2){ref-type="fig"}); this paralleled the small increase in lesion area observed in the aortic sinus of DKO mice.

Arsenical exposure did not increase lipid content ([Figure 2E](#f2){ref-type="fig"}) or macrophage infiltration ([Figure 2F](#f2){ref-type="fig"}) in the plaques of DKO mice. In addition, the lipid and macrophage content in plaques of unexposed DKO mice was not significantly different from that in control $\text{apoE}^{- / -}$ mice. These data suggest that As3MT is required for arsenic-induced lipid accumulation in macrophages. Considering our previous data implicating macrophage lipid homeostasis as an important target for arsenic ([@c32]; [@c33]), we further investigated the role of As3MT in arsenic-induced macrophage lipid accumulation *in vitro*. We cultured BMDMs from $\text{apoE}^{- / -}$ and DKO mice. BMDMs were exposed to 0.1 and $0.6\;\mu M$ $\text{NaAsO}_{2}$ (corresponding to 10 and $50\;\text{ppb}$ $\text{NaAsO}_{2}$) for 5 d during differentiation with M-CSF and then were challenged with 7-ketocholesterol for another 24 h. Consistent with our *in vivo* observations, $\text{NaAsO}_{2}$ increased the number of $\text{apoE}^{- / -}$ macrophages that stained positive for Oil Red O, indicating increased lipid accumulation in response to arsenic exposure ([Figure 2G](#f2){ref-type="fig"}). However, the DKO BMDM were protected against arsenic-increased lipid loading ([Figure 2G](#f2){ref-type="fig"}). These findings suggest that As3MT is required for arsenic-induced atherosclerosis. Moreover, As3MT expressed in macrophages is required for arsenic-mediated effects on lipid handling.

Effects of *As3mt* Deletion on Reactive Oxygen Species Formation in $\mathbf{apoE}^{- / -}$ Mice and in Primary Cells Present at the Atherosclerotic Lesion {#s3.3}
-----------------------------------------------------------------------------------------------------------------------------------------------------------

Increased reactive oxygen species (ROS) is a well-reported consequence of arsenic exposure ([@c10]; [@c64]). Furthermore, we have shown that inorganic arsenic induces ROS-mediated monocyte/endothelial cell interactions, an early event in atherosclerosis ([@c34]). Supplementation with the antioxidant selenium decreases arsenic-enhanced atherosclerosis ([@c31]). Therefore, we postulated that ROS may be differentially produced between the $\text{apoE}^{- / -}$ and DKO mice following arsenical exposure. Thus, we performed DHE staining to detect ROS in aortic sinus cross-sections from $\text{apoE}^{- / -}$ and DKO mice exposed to $200\;\text{ppb}$ arsenicals or tap water for 13 wk. All $\text{apoE}^{- / -}$ groups exposed to arsenicals had significantly increased intensity of DHE staining per vessel area when compared with controls ([Figure 3A](#f3){ref-type="fig"}). Surprisingly, neither inorganic nor methylated arsenicals induced ROS in the absence of As3MT expression ([Figure 3A](#f3){ref-type="fig"}). We then investigated whether specific cell types within the plaque were deficient in ROS production in the DKO mice *in vitro*. Thus, primary macrophages, SMCs, and endothelial cells were exposed to $200\;\text{ppb}$ $\text{NaAsO}_{2}$ for 30 min, stained with DHE, and analyzed using a fluorescence microscope. Interestingly, macrophages ([Figure 3B](#f3){ref-type="fig"}), endothelial cells ([Figure 3C](#f3){ref-type="fig"}), and SMCs ([Figure 3D](#f3){ref-type="fig"}) produced ROS in response to $\text{NaAsO}_{2}$ when derived from $\text{apoE}^{- / -}$ mice, but not when derived from DKO mice. Nevertheless, DKO-derived macrophages were not resistant to ROS induced by rotenone or menadione (see Figure S2A). DHE staining was reduced with antioxidants Tempol and *N*-acetylcysteine (Fig. S2B). Interestingly, the methylated arsenicals MMA III and DMA V also failed to increase ROS production in cells derived from DKO mice; however, DMA III increased ROS in both macrophages ([Figure 3E](#f3){ref-type="fig"}) and SMCs ([Figure 3F](#f3){ref-type="fig"}). These data indicate that As3MT expression, the methylation process, or both are required for arsenic-induced ROS in multiple cell types. Indeed, the ability of DMA III to induce ROS in DKO cells indicates that this terminal metabolite may be an important proatherogenic intermediate.

![Effects of *As3mt* deletion on reactive oxygen species (ROS) formation in $\text{apoE}^{- / -}$ mice and in primary cells present at the atherosclerotic lesion. Four-week-old $\text{apoE}^{- / -}$ and double knockout (DKO) mice were exposed to arsenicals \[*m*-sodium arsenite ($\text{NaAsO}_{2}$), monomethyl arsenic (MMA) V, MMA III, or dimethyl arsenic (DMA) V\] at $200\;\text{ppb}$ for 13 wk or maintained on tap water. Frozen sections ($\geq 3$ sections per animal; $n > 3$ per group) of the aortic sinus were stained with $2\;\mu M$ dihydroethidium (DHE), and ROS levels were expressed as a percentage of the total vessel area (*A*). Representative pictures are shown. The scale bar represents $200\mu m$. Bone marrow--derived macrophage (BMDM) (*B* and *E*), endothelial cells (*C*), and smooth muscle cells (*D* and *F*) derived from $\text{apoE}^{- / -}$ or DKO mice were pretreated with $5\;\mu M$ DHE for 10 min, and then the cultures were exposed to $200\;\text{ppb}$ $\text{NaAsO}_{2}$, MMA III, DMA V, or DMA III for another 30 min. Data are expressed as the $\text{mean} \pm \text{standard}\,\text{error}\,\text{of}\,\text{the}\,\text{mean}\,\left( \text{SEM} \right)$ from three independent experiments. \*$p < 0.05$; \*\*$p < 0.01$ relative to their own control.](EHP806_f3){#f3}

*As3mt* Expression in Macrophages, SMCs and Endothelial Cells {#s3.4}
-------------------------------------------------------------

Clearly, *As3mt* deletion inhibits arsenic-induced ROS and atherosclerosis following exposure to either $\text{NaAsO}_{2}$ or methylated arsenicals. As3MT is highly expressed in the liver, but very little is known about which cell types in atherosclerotic plaque express As3MT and whether it is functional. Deletion of As3mt reduces ROS production in the aortic sinus; thus, we postulated that plaque-resident cells could express As3MT and produce methylated intermediates *in situ*.

Plaque-resident macrophages are heterogeneous and include the inflammatory M1 and alternative wound-healing M2 polarization states ([@c14]). Thus, we evaluated the expression of *As3MT* in BMDMs that were differentiated and polarized *in vitro*. Macrophages were cultured with classical stimuli for polarization: M0 (M-CSF), M1 ($\text{IFN} - \gamma$), and M2 (IL-4). After polarization, cells were exposed to vehicle or to $50\;\text{ppb}$ $\text{NaAsO}_{2}$ for 24 h. A lower concentration of $\text{NaAsO}_{2}$ was chosen because differentiated macrophages are sensitive to the cytotoxic effects of $200\;\text{ppb}$ $\text{NaAsO}_{2}$ at longer time points *in vitro*. As3mt mRNA was detected in all three polarized BMDMs, although at a much lower level than the expression in murine liver ([Figure 4A](#f4){ref-type="fig"}). Next, protein expression was determined by performing Western blotting using a rabbit polyclonal antibody that we produced. As3MT protein could be detected in all macrophage subtypes ([Figure 4B](#f4){ref-type="fig"}). In addition, As3MT protein was expressed in SMCs and in endothelial cells ([Figure 4C](#f4){ref-type="fig"}). Notably, exposure to $\text{NaAsO}_{2}$ did not alter As3MT protein levels. Finally, using HPLC/ICP-MS, we determined the capacity of these cell types to methylate arsenic. Methylated forms of arsenic were detected in the media from BMDMs ([Figure 4D](#f4){ref-type="fig"}) after arsenic exposure. Taken together, these data demonstrate that macrophages, SMCs, and endothelial cells express functional As3MT, and consequently, local arsenic methylation might be important for the pathogenesis of arsenic-induced atherosclerosis.

![*As3mt* expression in macrophages, smooth muscle cells and endothelial cells. Total RNA from bone marrow--derived macrophage (BMDM) and liver from $\text{apoE}^{- / -}$ mice was isolated, and *As3mt* gene expression was assessed by real-time polymerase chain reaction (qPCR). Each sample was analyzed in triplicate (technical replicate) and expressed relative to the *m36B4* housekeeping gene (arbitrary units) (*A*). Immunoblots for As3MT were performed from whole cell extracts of BMDM (*B*), endothelial cells or smooth muscle cell (SMC) cultures (*C*) exposed to sodium arsenite ($\text{NaAsO}_{2}$) at the time and concentration indicated. Three independent experiments were performed. Arsenic methylation profiles in the media from BMDM (*D*) were assessed by high performance liquid chromatography--inductively coupled plasma--mass spectrometry (HPLC-ICP-MS). iAs, inorganic arsenic; MMA, monomethyl arsenic; DMA, dimethyl arsenic.](EHP806_f4){#f4}

Effects of Bone Marrow-Derived and Non-Bone Marrow--Derived *As3mt* on Arsenic-Induced Atherosclerosis {#s3.5}
------------------------------------------------------------------------------------------------------

Based on our data showing that As3MT is expressed in macrophages, endothelial cells, and SMCs, we investigated the relative contribution of bone marrow-derived versus non-bone marrow--derived As3MT on arsenic-induced atherosclerosis. We performed bone marrow transplantations in which male $\text{apoE}^{- / -}$ or DKO mice were irradiated and reconstituted with either $\text{apoE}^{- / -}$ or DKO bone marrow. After 4 wk of reconstitution, mice were maintained on tap water or were transferred to $200\;\text{ppb}$ $\text{NaAsO}_{2}$ for another 13 wk. $\text{apoE}^{- / -}$ mice transplanted with $\text{apoE}^{- / -}$ bone marrow and exposed to $200\;\text{ppb}$ $\text{NaAsO}_{2}$ showed increased plaque formation when compared with tap water controls ([Figure 5A](#f5){ref-type="fig"}; see also Figure S3), which recapitulated the results that we have published previously ([@c32]). Furthermore, DKO mice transplanted with DKO bone marrow were protected against arsenic-induced atherosclerosis. Interestingly, neither $\text{apoE}^{- / -}$ mice transplanted with DKO bone marrow nor DKO mice reconstituted with $\text{apoE}^{- / -}$ bone marrow had increased lesion size after $\text{NaAsO}_{2}$ exposure compared with their respective controls ([Figure 5A](#f5){ref-type="fig"}; see also Figure S3). We did observe that $\text{apoE}^{- / -}$ mice transplanted with DKO bone marrow had a significantly increased basal level of plaque compared with $\text{apoE}^{- / -}$ mice transplanted with $\text{apoE}^{- / -}$ bone marrow ([Figure 5A](#f5){ref-type="fig"} and Figure S3). DKO mice reconstituted with DKO bone marrow also had slightly elevated levels of plaque size consistent with what we observed in [Figure 2](#f2){ref-type="fig"}. Lipid ([Figure 5B](#f5){ref-type="fig"}) and SMC ([Figure 5D](#f5){ref-type="fig"}) content were reduced only in $\text{apoE}^{- / -}$ mice transplanted with $\text{apoE}^{- / -}$ bone marrow. Collectively, the data reveal that both host- and bone marrow-derived cells participate in arsenic methylation and are mandatory for arsenic-induced atherosclerosis.

![Effects of bone marrow--derived and non-bone marrow--derived *As3mt* on arsenic-induced atherosclerosis. Five-week-old $\text{apoE}^{- / -}$ or double knockout (DKO) male mice were lethally irradiated and transplanted as indicated. Transplanted 9-wk-old $\text{apoE}^{- / -}$ mice with $\text{apoE}^{- / -}$ bone marrow (BM), DKO mice with $\text{apoE}^{- / -}$ BM, $\text{apoE}^{- / -}$ mice with DKO BM, and DKO mice with DKO BM were exposed to $200\;\text{ppb}$ *m*-sodium arsenite ($\text{NaAsO}_{2}$) for 13 wk or maintained on tap water. Sections of the aortic sinus were stained with Oil Red O, and the percentage of the lesion area was evaluated relative to the total aortic sinus area (*A*). The lipid content was evaluated relative to the total lesion area (*B*). The macrophage composition (*C*), $\alpha$ smooth muscle cell actin (*D*), and collagen (*E*) were also evaluated relative to the total lesion area. Values are expressed as the $\text{mean} \pm \text{standard}\,\text{error}\,\text{of}\,\text{the}\,\text{mean}\,\left( \text{SEM} \right)$. \*$p < 0.05$; \*\*$p < 0.01$; \*\*\*$p < 0.001$ relative to their own control.](EHP806_f5){#f5}

Discussion {#s4}
==========

Epidemiologic studies have linked arsenic exposure to increased cardiovascular disease. However, the contribution of arsenic biomethylation is unclear. We used our mouse model of arsenic-enhanced atherosclerosis to investigate the impact of the methylation process. We show that methylated arsenicals are proatherogenic, and like inorganic arsenic, alter plaque components toward a more unstable, rupture-prone phenotype. We also demonstrate that only arsenicals that undergo biotransformation are proatherogenic, supported by data showing that arsenobetaine does not increase plaque formation. Furthermore, we show that $\text{apoE}^{- / -}$ mice that also lack the enzyme that catalyzes arsenic methylation, As3MT, are protected from arsenic-, but not high-fat diet--, induced atherosclerosis. Our data also support the conclusion that arsenic biotransformation is not necessarily a detoxification process but rather is required for its proatherogenic effects.

Humans are exposed to methylated arsenicals ([@c52]), but their impact on public health has been underestimated and under-evaluated. Methylated arsenicals are found in the air ([@c70]), soil ([@c44]), and water ([@c59]; [@c60]; [@c72]). The relative toxicities of methylated arsenicals have been investigated *in vitro* and *in vivo*. MMA III is more cytotoxic than inorganic arsenic or DMA in cell culture systems ([@c66]). Similar results were observed in an endothelial cell line, where inorganic arsenic and monomethylarsonous acid diglutathione \[${\text{MMA}\,\text{III}\left( \text{GS} \right)}_{2}$\] were more cytotoxic than MMA V and DMA V ([@c26]). MMA III and inorganic arsenic inhibit differentiation of embryonic stem cells to the same degree, whereas DMA III has reduced effects ([@c43]). *In vivo*, methylated arsenicals can cause hyperplasia in urothelial cells ([@c17]). Specifically, MMA III induces proliferation and tumorigenesis in a human urothelial cell line ([@c9]). DMA V--exposed rats pretreated with carcinogens developed a broad range of tumors in different organs ([@c75]). To our knowledge, the present study is the first to show noncancer-related effects of low-moderate concentrations of methylated arsenicals *in vivo*.

Our data show that not only are methylated arsenicals proatherogenic but also that *As3mt* is required for the proatherogenic effects of arsenic in the $\text{apoE}^{- / -}$ model. This result suggests that alterations in As3MT function could be correlated with the risk of atherosclerosis. Several genetic polymorphisms in the *AS3MT* gene have been described in humans, some of which alter the enzymatic efficiency ([@c19]; [@c20]; [@c21]; [@c39]; [@c40]; [@c55]). Indeed, arsenic methylation capacity, as measured by the presence of methylated arsenicals in the urine, is inversely associated with risk of developing disease, including cardiovascular disease ([@c13]; [@c56]). *AS3MT* SNPs are associated with atherosclerotic markers in humans, although these data were not significant after correcting for multiple comparisons ([@c74]). Our results support the hypothesis that *As3MT* is an important mediator of the proatherogenic effects of arsenic and should be reevaluated in multiple cohorts.

Macrophages are the main cell type that uptake and accumulate lipids at the atherosclerotic site, and they are required for generation of the atherosclerotic plaque ([@c36]; [@c67]). Our previous data implicated macrophages as key cellular targets in arsenic-enhanced atherosclerosis through increased lipid accumulation owing to inhibition of efflux pathways controlled by the liver X receptor ([@c33]; [@c54]). We now extend these data by showing that As3MT is essential for arsenic-induced lipid accumulation in macrophages. Furthermore, our transplant studies support the concept of extrahepatic metabolism of arsenic because *As3mt* expression was required in both the hematopoietic and nonhematopoietic tissue to support the full proatherogenic effects of arsenic. Indeed, we found that As3MT is expressed and functional in several of the key cell types in atherosclerotic plaque: macrophages, endothelial cells, and SMCs. These cell types are known to be targets of arsenic toxicity ([@c8]; [@c27]; [@c35]; [@c34]; [@c41]; [@c62]; [@c63]; [@c64]; [@c65]), which leads to the intriguing possibility that arsenic methylation can occur at the site of an atherosclerotic lesion rather than only occurring in the liver with methylated arsenicals traveling to the lesion. Generation of a floxed-*As3mt* mouse is required to delineate which cells contribute to arsenic methylation in the plaque leading to atherosclerosis.

Arsenic is well known to stimulate ROS production ([@c64]; [@c6]; [@c7]; [@c50]). The extent of arsenic-induced atherosclerosis correlates with ROS within the plaques (Krohn et al. 2016). Here, we provide evidence that arsenic methylation is required for arsenic-induced ROS production *in vitro* and *in vivo*. Arsenic metabolism is required for arsenic-induced oxidative DNA damage in murine and human cell models of carcinogenicity ([@c30]). However, the same group has shown that MMA III increases oxidative DNA damage in a methylation-deficient cell line ([@c53]). This finding contrasts with our data, where $\text{NaAsO}_{2}$ and MMA III did not induce ROS in the DKO mouse vessels and primary cells. This discrepancy could be due to the differences between primary cells, cell lines, and animals; to the $\text{apoE}^{- / -}$ background; or to the use of knockout versus poorly methylating cells. Nevertheless, our findings are intriguing and suggest that arsenic methylation is important in ROS production. Indeed, DMA III did induce ROS in cells derived from DKO mice, suggesting that this terminal metabolite may drive ROS production. Alternatively, DMA III may not be the terminal metabolite if the trimethylated form of arsenic is produced and triggers ROS production. However, this process would have to be independent of As3MT, requiring an alternate arsenic methyltransferase. ROS is one of many important factors driving atherosclerosis. Unfortunately, DMA III is too unstable to utilize in *in vivo* experiments; thus, we do not know whether DMA III would be proatherogenic in the DKO mice. Further investigation will focus on confirming DMA III--induced ROS production using multiple assays, including measures of downstream oxidative damage in the presence and absence of As3MT.

One could also hypothesize that As3MT may have other unknown functions. Although no functions have been described for As3MT beyond arsenic methylation, different metabolomic profiles have been observed in wild-type and ${{As}3\text{mt}}^{- / -}$ mice in the absence of arsenic ([@c28]). In addition, a genome-wide association study investigating the schizophrenia-associated locus linked a polymorphism in the first exon to generation of an alternatively spliced As3MT isoform, which is potentially a molecular marker for this psychiatric disease ([@c37]). Given that *As3MT* lies near genes with metabolic functions on chromosome 19, perhaps deletion of exons 3--5 in the *As3MT* gene may alter the expression of nearby genes. We measured the expression of selected genes (see Table S3) upstream or downstream of *As3mt* in liver or brain of $\text{apoE}^{- / -}$ or DKO mice exposed to tap water, inorganic arsenite, or methylated arsenicals. There was variation between animals, but we found statistically significant increases in Nt5c2 mRNA in the brains of DKO mice exposed to arsenicals, and decreases in Usmg5 mRNA expression in DKO mouse livers, compared with $\text{apoE}^{- / -}$ mice (see Figure S4). Whether these changes result in similar protein changes and are functionally relevant to arsenic toxicity remains undefined.

In additional support of an alternate As3MT function, deletion of *As3mt* from $\text{apoE}^{- / -}$ mice mildly increased the basal plaque size at 17 wk of age in the aortic sinus ([Figure 2](#f2){ref-type="fig"}), which was also observed in DKO mice transplanted with DKO bone marrow ([Figure 5](#f5){ref-type="fig"}). A higher basal level of plaque was also observed in $\text{apoE}^{- / -}$ mice reconstituted with DKO bone marrow ([Figure 5](#f5){ref-type="fig"}). These increases in basal plaque levels upon *As3mt* deletion were modest compared with those observed in mice fed a high-fat diet, although thus far, we have only tested mice at this relatively early time point in atherogenesis. Nevertheless, our data suggest that As3MT may protect against atherosclerosis in the absence of arsenic. Perhaps when present, arsenic quenches or sequesters As3MT, preventing antiatherogenic functions; this could explain both the increased basal plaque level upon *As3mt* deletion and the lack of arsenic-enhanced atherosclerosis in the DKO mice, even upon exposure to methylated arsenicals.

Conclusion {#s5}
==========

In summary, our data indicate a key role for *As3MT* in mediating the atherosclerotic effects of arsenic. *AS3MT* SNPs may be useful biomarkers for identifying those at greatest risk for developing cardiovascular toxicity associated with arsenic exposure.
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